Business Context and Reporting Period
Company: Precision Optics Corporation, Inc. (POCI)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended December 31, 2024
Business Overview: The Company designs and manufactures advanced optical instruments, including 3D endoscopes, microprecision lenses, and custom optical components for medical, defense, and industrial applications. Operations include three divisions: Precision Optics, Ross Optical Industries, and Lighthouse Imaging.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Total Revenues | $4,526,907 | $8,723,960 |
| Gross Profit | $1,069,942 | $2,187,272 |
| Gross Margin | 23.6% | 25.1% |
| Net Loss | $(969,681) | $(2,280,928) |
| Loss Per Share (Basic & Diluted) | $(0.15) | $(0.36) |
| Cash and Cash Equivalents | $212,441 (as of Dec 31, 2024) | N/A |
| Revolving Line of Credit Outstanding | $900,000 | N/A |
| Long-Term Debt (Net) | $1,611,944 | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 6.2% ($297,382) for the quarter and 4.6% ($421,584) for the six months compared to the prior year periods.
- Segment Performance:
- Engineering Design Services: Decreased 46.8% (quarter) and 26.7% (six months) due to reduced demand and project transitions to manufacturing.
- Optical Components: Increased 50.8% (quarter) and 30.4% (six months) driven by new defense/aerospace and medical programs.
- Finished Products: Decreased 41.7% (quarter) and 45.0% (six months) due to lower demand and timing of order fulfillment.
- Margin Compression: Gross margin declined from 30.1% to 23.6% (quarter) and from 31.9% to 25.1% (six months), attributed to product mix changes and revenue decreases.
- Expense Trends:
- R&D expenses increased 43.3% (quarter) and 65.3% (six months) to support new technology development.
- SG&A expenses decreased 14.0% for the quarter due to lower bad debt and stock-based compensation, but increased 1.0% for the six-month period.
- Cash Flow: Net cash used in operating activities improved to $1.1 million (six months) from $1.5 million in the prior year, aided by increased accounts payable and customer advances.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, operating cash flow, and credit line availability are sufficient for 12 months. However, the Company may require external financing if operating cash is insufficient.
- Debt Covenant Waiver: The Company did not meet its annual debt service coverage ratio covenant for the fiscal year ended June 30, 2024. The lender granted a waiver and amended the loan terms to allow interest-only payments from October 2024 through March 2025.
- Capital Raise: In August 2024, the Company completed a registered direct offering, raising net proceeds of approximately $1.2 million.
- Internal Controls: Material weaknesses regarding inventory valuation and R&D capitalization identified in the prior fiscal year were remediated as of September 30, 2024.
- Risks: The Company faces high competition, reliance on specific customers, and the need to transition engineering projects to production to sustain revenue.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the status of the debt service coverage ratio waiver and the impact of the interest-only payment period on future cash flow.
- Inventory Valuation: Confirm the effectiveness of the new ERP system and inventory costing methodology following the remediation of prior material weaknesses.
- Revenue Mix Sustainability: Assess the durability of the growth in Optical Components versus the decline in Engineering Design Services and Finished Products.
- Liquidity Runway: Monitor cash burn rates and the utilization of the remaining $350,000 available on the revolving line of credit.
- Customer Concentration: Review the allowance for credit losses ($121,901) and any potential concentration risks in the defense or medical sectors.